Vytorin As Strategy To Reduce Dislipidemia In Adults (0653A-148)

• Status: Completed
• Trial end date: 2005-12-23
• Target enrollment: 0
• Participant gender: All

Summary

This study is intended to allow physicians to check the superior clinical efficacy of Vytorin compared to atorvastatin, as the most adequate therapy using the ATP-III goals achievement and cardiovascular risk reduction in adult patients with dislipidemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Simvastatin

Criteria

Inclusion Criteria:

• Patients Who Voluntary Accept To Participate In The Study After Been Informed By The Doctor And Signed The Informed Consent Form.

Exclusion Criteria:

• Any Another Kind Of Contraindication For Use Of Statins

• Hypersensitivity To Any Of The Active Ingredients

• Increased Serum Hepatic Enzymes (Over 3 Times Only)

• Patients With Severe Hepatic Insufficiency

• Women who are Pregnant or Potentially Pregnant